Objective: Vismodegib is the first-in-class oral small molecule inhibitor in advanced basal cell carcinoma (BCC). We herein report the treatment experience with vismodegib at the oncology department of the Gaziantep university medical faculty. Material and Methods: This was a retrospective analyze of consecutive 15 BCC patients with locally advanced and metastatic stage between August 2016 and June 2019. While the primary endpoint was progression free survival, secondary endpoints were efficacy and toxicity. Results: The mean duration of treatment was 9.1 months on vismodegib (range, 0.97-28.60 months) with a lengthy median follow-up time of 17.6 months. The overall response rate (ORR) was 73.3%, with 20% (n=3) of patients having complete response, 53.3% (n=8) having partial response and 20% (n=3) exhibiting stable disease. Progression was observed in 6.7% of the patients. Eight patients (%53) discontinued the treatment. The most common reason for discontinuation was drug side-effects (%53). Mainly side-effects (all grades) were fatigue (80%), muscle cramps (60%), loss of appetite (53.3%) and dysgeusia (46.6%). The median PFS was 9.66 months (95% CI; 2.05-17.28). Conclusion: Our PFS results seem contradictory to the reports indicating longer PFS with vismodegib, in the lack of difference in response rate. This study also confirmed that vismodegib has notable adverse effects in agreement with previous reports. The most frequently encountered problem was high dropout rates of treatment. It seems essential to manage toxicity and provide coping strategies for adverse effects in daily clinical practice. It was considered higher dropout from treatment may be associated with shortened PFS.